Autosomal-dominante polyzystische Nierenerkrankung – Erste krankheitsmodifizierende Therapie zugelassen

• Literatur

• 1 Torres VE, Chapman AB, Devuyst O et al.; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
• 2 Grantham JJ, Torres VE, Chapman AB et al.; CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
• 3 Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301